A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

• MRTX849 is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C).

In this study, the sponsor and investigators want to learn:

• How much of the study drug can be given with an acceptable level of side effects
• The effects of the study drug (good and bad)
• How much of the study drug is absorbed into the blood and how fast it is removed
• How the study drug is acting on your body
• If research tests can be used in the future to predict who will benefit from MRTX849

The study is divided into 2 phases. In the first phase (Phase 1), small groups of patients received MRTX849 at increasing doses until the dose that was tolerable to most patients was identified. This phase of the study has identified the starting dose that will be used in the next phase of the study.

In the second phase (Phase 2), the study will enroll patients with specific types of cancer (like lung cancer or colon cancer) that have the target gene mutation to measure the number of patients that experience tumor shrinkage during treatment with MRTX849.